MTT #109: Healthcare affordability, GLP-1s and the patient revolt ahead
About this episode
The episode discusses the rising costs of healthcare and the implications for Americans, focusing on affordability and the role of GLP-1 medications.
In this week’s episode of Medicine: The Truth , hosts Jeremy Corr and Dr. Robert Pearl dig for the facts beneath healthcare’s biggest headlines. Today’s show opens with the issue most likely to shape how Americans think about healthcare heading into the midterm elections: affordability. Dr. Pearl explains that medical costs have now reached $5.7 trillion, rising more than 7% for the third consecutive year. Federal actuaries project that healthcare spending could approach $9 trillion by 2034, accounting for more than 20% of the U.S. GDP. For voters, employers, patients and families, those numbers aren’t just an endless string of zeroes. They’re impacting everyday life. Premiums, deductibles, copays and prescription drug costs are forcing people with private insurance, Medicare and exchange coverage to delay care, take on debt or choose worse coverage. Two major drivers stand out: hospital spending and drug costs. Hospital care remains the largest share of national healthcare expenses, while drug spending is rising fastest, driven in part by the growing use of GLP-1 medications. Pearl sees enormous potential in these drugs to improve health and reduce complications over time, but…
More episodes of Fixing Healthcare Podcast
- FHC #227: Dr. Rod Rohrich on social media, science and AI-powered care
- FHC #226: Peptides, primary care & the false choices in American medicine
- MTT #110: Peptides, politics & the perils of medicine without evidence
- FHC #225: Kindness, burnout and the limits of medical leadership
- FHC #224: Austin Chiang on burnout, misinformation and the future of med-tech
- FHC #223: How GenAI & World Cup strategy can help fix healthcare
Explore listener stats, chart rankings, contacts and more on the Fixing Healthcare Podcast podcast page.